QuantLogix ← EW scorecard
📅 EW Earnings Preview
Edwards Lifesciences Corp
Next report (est.)
September 19, 2026
Countdown
98 days
EPS growth YoY
+8.2%
Revenue growth YoY
+16.7%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
May 6, 2026 ±2.7% +0.3% over-priced
November 5, 2025 ±3.6% -1.6% over-priced
August 6, 2025 ±2.2% -0.8% over-priced
May 6, 2025 ±2.1% -0.3% over-priced
November 6, 2024 ±3.3% -1.4% over-priced
July 31, 2024 ±11.9% -0.9% over-priced
April 29, 2024 ±2.3% -0.6% over-priced
October 27, 2023 ±6.0% -1.7% over-priced
Across these reports, options implied an average ±4.3% move vs an actual average of 0.9% — the stock stayed inside the implied band 100% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q1 FY2026 $0.66 $1.6B $381M
Q4 FY2025 $0.16 $1.6B $91M
Q3 FY2025 $0.50 $1.6B $290M
Q2 FY2025 $0.56 $1.5B $332M
Analyst posture
Buy / Strong Buy
31
Hold
11
Sell
0
Stable: -1 net change 30d
Live 5-factor engine read: Buy · 54/100 Full scorecard →
Get alerted before every EW report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on EW before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Edwards Lifesciences Corp (EW) reports in 98 days, with the next report estimated for September 19, 2026. Across the last 8 reports, options priced an average ±4.3% earnings move while the stock actually moved 0.9% on average — the market has systematically over-priced EW's earnings risk. Fundamentals into the print: EPS up 8.2% year-over-year, revenue up 16.7%. QuantLogix's live 5-factor engine currently reads EW as a buy at 54/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →